Lovastatin , Analysis of standard products, ≥98% , 75330-75-5

Synonym(s):
2-Methyl-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthalenyl ester butanoic acid;6-α-Methylcompactin;Lovastatin;Mevinolin;Monacolin K

CAS NO.：75330-75-5

Empirical Formula: C24H36O5

Molecular Weight: 404.54

MDL number: MFCD00072164

EINECS: 616-212-7

PRODUCT Properties

• Melting point: 175°C
• alpha: D25 +323° (c = 0.5 g in 100 ml acetonitrile)
• Boiling point: 559.2±50.0 °C(Predicted)
• Density: 1.12±0.1 g/cm3(Predicted)
• vapor pressure: 0Pa at 25℃
• refractive index: 320 ° (C=0.5, CH3CN)
• storage temp.: -20°C
• solubility: ethanol: soluble9.80-10.20mg/mL, clear, colorless to faintly yellow
• pka: 13.49±0.40(Predicted)
• form: White to off-white powder
• color: White
• Water Solubility: 0.0004 mg/mL at 25 ºC
• Merck: 14,5586
• BCS Class: 2
• Stability: Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 2 months.
• LogP: 4.260

Description and Uses

Lovastatin is an orally-active hypocholesterolemic useful in the treatment of familial hypercholesterolemia. The drug acts by inhibiting the HMG-CoA reductase-catalyzed rate limiting step of cholesterol biosynthesis. While treatment with lovastatin leads to significant reductions in total and LDL cholesterol, its effect on atherosclerosis or coronary heart disease has not been established.

Cardiovascular

Safety

• Symbol(GHS): GHS08
• Signal word: Warning
• Hazard statements: H351-H361f
• Precautionary statements: P201-P202-P280-P308+P313-P405-P501
• Hazard Codes: Xi
• Risk Statements: 36/37/38
• Safety Statements: 22-24/25-36/37/39-26
• RIDADR: 3077
• WGK Germany: 3
• RTECS: EK7907000
• HazardClass: 9
• PackingGroup: III
• HS Code: 29322090
• Toxicity: LD50 orally in mice: >1000 mg/kg (Endo)